However, studies have also indicated that double deletion of ARID1A and ARID1B can trigger rapid carcinogenesis in the liver and skin of mice, suggesting caution should be exercised when employing homologous therapy for treating cancers with mutated ARID1 [64]. Here, ARID1B is linked to cancer.